NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

April 22, 2025

Study Completion Date

April 22, 2025

Conditions

Thyroid Eye DiseaseGraves OphthalmopathyGraves OrbitopathyThyroid Associated OphthalmopathyEndocrine System DiseasesOrbital DiseasesProptosisEye Diseases

Interventions

DRUG

LASN01

Low dose of LASN01 will be administered intravenously.

DRUG

LASN01

High dose of LASN01 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

DRUG

LASN01

High dose of LASN01 will be administered intravenously.

Trial Locations (15)

14012

Site 302, Córdoba

28403

Site 110, Wilmington

33136

Site 103, Miami

41009

Site 301, Seville

48152

Site 108, Livonia

77030

Site 106, Houston

77401

Site 104, Houston

89144

Site 112, Las Vegas

90210

Site 111, Beverly Hills

92093

Site 101, San Diego

94303

Site 105, Palo Alto

98104

Site 109, Seattle

EC1V 2PD

Site 201, London

NW1 5QH

Site 206, London

NE1 4LP

Site 204, Newcastle upon Tyne